Cargando…

Factors Modifying Outcome After MIBG Therapy in Children With Neuroblastoma—A National Retrospective Study

BACKGROUND: Neuroblastoma is the most common pediatric extracranial tumor with varied prognoses, but the survival of treated refractory or relapsing patients remains poor. OBJECTIVE: This analysis presents the outcomes of children with neuroblastoma undergoing MIBG therapy in Poland in 2006-2019. ST...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ussowicz, Marek, Wieczorek, Aleksandra, Dłużniewska, Agnieszka, Pieczonka, Anna, Dębski, Robert, Drabko, Katarzyna, Goździk, Jolanta, Balwierz, Walentyna, Handkiewicz-Junak, Daria, Wachowiak, Jacek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075349/ https://www.ncbi.nlm.nih.gov/pubmed/33912462 http://dx.doi.org/10.3389/fonc.2021.647361

Ejemplares similares

Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Segmental chromosomal aberrations as the poor prognostic factor in children over 18 months with stage 3 neuroblastoma without MYCN amplification
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Risk Factors for Transplant Outcomes in Children and Adolescents with Non-Malignant Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation
por: Zaucha-Prażmo, Agnieszka, et al.
Publicado: (2019)

The role of N-Myc gene amplification in neuroblastoma childhood tumour – single-centre experience
por: Kaczówka, Przemysław, et al.
Publicado: (2018)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Disseminated Juvenile Xanthogranuloma and Hemophagocytic Lymphohistiocytosis Developed During Treatment of Acute Lymphoblastic Leukemia: Case Report
por: Pawińska-Wa̧sikowska, Katarzyna, et al.
Publicado: (2020)

The Role of Id2 Protein in Neuroblatoma in Children
por: Wieczorek, Aleksandra, et al.
Publicado: (2015)

Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain
por: Szewczyk, Katarzyna, et al.
Publicado: (2019)

Isolated central nervous system relapses in patients with high-risk neuroblastoma -clinical presentation and prognosis: experience of the Polish Paediatric Solid Tumours Study Group
por: Wieczorek, Aleksandra, et al.
Publicado: (2022)

Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival
por: Krajewska, Jolanta, et al.
Publicado: (2020)

Venetoclax Use in Paediatric Haemato-Oncology Centres in Poland: A 2022 Survey
por: Bobeff, Katarzyna, et al.
Publicado: (2023)

The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro.
por: Armour, A., et al.
Publicado: (1997)

The Malposition of Central Venous Catheters in Children
por: Dzierzega, Maria, et al.
Publicado: (2014)

Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia
por: Pawinska-Wasikowska, Katarzyna, et al.
Publicado: (2022)

Molecular Genetics Diversity of Primary Hemophagocytic Lymphohistiocytosis among Polish Pediatric Patients
por: Bąbol-Pokora, Katarzyna, et al.
Publicado: (2021)

MIBG Therapy for Neuroblastoma: Precision Achieved With Dosimetry, and Concern for False Responders
por: Rubio, Pedro M., et al.
Publicado: (2020)

Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes
por: Blom, Thomas, et al.
Publicado: (2021)

The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013)

Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
por: George, Sally L., et al.
Publicado: (2016)

Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma
por: Krajewska, Jolanta, et al.
Publicado: (2019)

Gastrointestinal peptides in children before and after hematopoietic stem cell transplantation
por: Skoczeń, Szymon, et al.
Publicado: (2020)

Outcome of refractory and relapsed acute myeloid leukemia in children treated during 2005–2011 – experience of the Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG)
por: Skalska-Sadowska, Jolanta, et al.
Publicado: (2014)

Genetic Profile and Clinical Implications of Hepatoblastoma and Neuroblastoma Coexistence in a Child
por: Skoczen, Szymon, et al.
Publicado: (2019)

Plasma levels of leptin and soluble leptin receptor and polymorphisms of leptin gene -18G > A and leptin receptor genes K109R and Q223R, in survivors of childhood acute lymphoblastic leukemia
por: Skoczen, Szymon, et al.
Publicado: (2011)

123I‐MIBG scintigraphy and 18F‐FDG‐PET imaging for diagnosing neuroblastoma
por: Bleeker, Gitta, et al.
Publicado: (2015)

The assessment of side effects of tyrosine kinase inhibitors (TKI) applied in patients with advanced thyroid cancer (TC) - one centre experience
por: Krajewska, Jolanta, et al.
Publicado: (2013)

Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes
por: Kukulska, Aleksandra, et al.
Publicado: (2020)

Analysis of quantitative [I-123] mIBG SPECT/CT in a phantom and in patients with neuroblastoma
por: Brady, Samuel L., et al.
Publicado: (2019)

Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma – Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015
por: Czarniecka, Agnieszka, et al.
Publicado: (2021)

Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
por: Kukulska, Aleksandra, et al.
Publicado: (2010)

Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer
por: Ledwon, Aleksandra, et al.
Publicado: (2021)

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma
por: DuBois, S G, et al.
Publicado: (2015)

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy
por: Lode, Holger N., et al.
Publicado: (2023)

Go with the Flow—Early Assessment of Measurable Residual Disease in Children with Acute Lymphoblastic Leukemia Treated According to ALL IC-BFM2009
por: Pawinska-Wasikowska, Katarzyna, et al.
Publicado: (2022)

Using systematic reviews to identify research gaps - a case study: mIBG for the treatment of neuroblastoma in children
por: Wilson, Jayne, et al.
Publicado: (2013)

I-131 mIBG Scintigraphy Curie Versus SIOPEN Scoring: Prognostic Value in Stage 4 Neuroblastoma
por: Riaz, Saima, et al.
Publicado: (2018)

Comparison Between Diffusion‐Weighted MRI and (123)I‐mIBG Uptake in Primary High‐Risk Neuroblastoma
por: Privitera, Laura, et al.
Publicado: (2020)

Analysis of incidence and risk factors of the multidrug resistant gastrointestinal tract infection in children and adolescents undergoing allogeneic and autologous hematopoietic cell transplantation: a nationwide study
por: Salamonowicz-Bodzioch, Małgorzata, et al.
Publicado: (2021)

Long‐term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC‐BFM 2002 trial
por: Kowalczyk, Jerzy R., et al.
Publicado: (2019)

(131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients
por: Garaventa, A, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_sm4fb1u6lb1uh59cjml513nomo